FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes

Author:

Samms Ricardo J.1ORCID,Cheng Christine C.1,Fourcaudot Marcel2,Heikkinen Sami3,Khattab Ahmed2,Adams John2,Cersosimo Eugenio2,Triplitt Curtis2,Puckett Curtis2,Tsintzas Kostas4ORCID,Adams Andrew. C.1,Abdul-Ghani Muhammad A.2,DeFronzo Ralph A.1,Norton Luke2ORCID

Affiliation:

1. Eli Lilly and Company, Indianapolis, Indiana

2. Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas

3. Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland

4. School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom

Abstract

In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D.

Funder

American Diabetes Association

Amylin Pharmaceuticals

AstraZeneca

Bristol-Myers Squibb

HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

American Physiological Society

Subject

Physiology (medical),Physiology,Endocrinology, Diabetes and Metabolism

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3